We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.38B
AUM Growth
+$319M
Cap. Flow
-$50.3M
Cap. Flow %
-0.6%
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$304M
2
ELV icon
Elevance Health
ELV
+$123M
3
XRAY icon
Dentsply Sirona
XRAY
+$102M
4
AGN
Allergan plc
AGN
+$95.1M
5
INSP icon
Inspire Medical Systems
INSP
+$78.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$185M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$154M
3
ABBV icon
AbbVie
ABBV
+$145M
4
THC icon
Tenet Healthcare
THC
+$119M
5
BMY icon
Bristol-Myers Squibb
BMY
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.69%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
76
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$24.9M 0.3%
5,000,000
– –
RNAC icon
77
Cartesian Therapeutics
RNAC
$226M
$24.4M 0.29%
61,427
– –
HCA icon
78
HCA Healthcare
HCA
$90.6B
$24.3M 0.29%
237,300
-245,100
-51% -$24.8M
SYK icon
79
Stryker
SYK
$134B
$24.2M 0.29%
143,400
-92,900
-39% -$15.6M
MGLN
80
DELISTED
Magellan Health Services, Inc.
MGLN
$24.1M 0.29%
251,383
-312,460
-55% -$30M
ABT icon
81
Abbott
ABT
$190B
$24M 0.29%
394,100
– –
NTLA icon
82
Intellia Therapeutics
NTLA
$1.49B
$24M 0.29%
876,000
-237,000
-21% -$5.74M
AMGN icon
83
Amgen
AMGN
$213B
$22.9M 0.27%
124,100
-321,210
-72% -$56.8M
RDUS
84
DELISTED
Radius Health, Inc.
RDUS
$22.5M 0.27%
762,900
– –
HUM icon
85
Humana
HUM
$43.1B
$21.6M 0.26%
+72,600
New +$21.3M
WHWK
86
Whitehawk Therapeutics
WHWK
$177M
$21.6M 0.26%
+346,263
New +$20.9M
SVA
87
DELISTED
Sinovac Biotech, Ltd
SVA
$21.2M 0.25%
2,839,500
– –
CHRS icon
88
Coherus Oncology
CHRS
$224M
$20.7M 0.25%
1,480,482
+13,682
+0.9% +$196K
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$20.2M 0.24%
4,040,000
+2,940,000
+267% +$15.1M
GBT
90
DELISTED
Global Blood Therapeutics, Inc.
GBT
$20.2M 0.24%
447,275
-1,019,255
-70% -$46.4M
SYBX
91
DELISTED
Synlogic
SYBX
$20M 0.24%
135,333
– –
SYRE icon
92
Spyre Therapeutics
SYRE
$8.49B
$19.7M 0.24%
74,621
+15,840
+27% +$3.9M
SCPH
93
DELISTED
scPharmaceuticals
SCPH
$19.3M 0.23%
3,409,865
– –
STDY
94
DELISTED
SteadyMed Ltd
STDY
$19.1M 0.23%
4,246,196
– –
KTWO
95
DELISTED
K2M Group Holdings, Inc
KTWO
$19M 0.23%
843,205
– –
NTRA icon
96
Natera
NTRA
$35.9B
$18.5M 0.22%
984,086
-592,104
-38% -$7.2M
ELDN icon
97
Eledon Pharmaceuticals
ELDN
$261M
$17.8M 0.21%
140,951
– –
VRNA
98
DELISTED
Verona Pharma
VRNA
$17.1M 0.2%
1,250,396
– –
PVLA
99
Palvella Therapeutics
PVLA
$2.04B
$15.9M 0.19%
39,250
-30,125
-43% -$14.3M
NVO
100
Novo Nordisk
NVO
$227B
$15.2M 0.18%
660,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2018 Portfolio in Review

As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
  • OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
  • OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
  • OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
  • OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
  • OrbiMed opened 20 new positions and closed 14 in Q2 2018.
  • OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.